Pear Therapeutics Stock

Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics (PDTs). The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better efficacy for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear’s lead products, reSET® and reSET-O®, are FDA-cleared PDTs for treating Substance Use Disorder (SUD) and Opiate Use DIsorder, respectively. Pear’s product development pipeline includes Somryst® for insomnia with depressive symptoms, as well as products for schizophrenia (Pear-004) and multiple sclerosis (Pear-006). Pear is developing and a portfolio of early-stage products across therapeutic areas.